WO2024212893 - LEVILACTOBACILLUS BREVIS AND USE THEREOF
National phase entry:
Publication Number
WO/2024/212893
Publication Date
17.10.2024
International Application No.
PCT/CN2024/086374
International Filing Date
07.04.2024
Title **
[English]
LEVILACTOBACILLUS BREVIS AND USE THEREOF
[French]
LEVILACTOBACILLUS BREVIS ET SON UTILISATION
[Chinese]
一株短发酵剂乳杆菌及其应用
Applicants **
IBIOME BIOTECHNOLOGY CO., LTD.
Inventors
ZHU, Shu
HU, Ji
WEN, Wen
TAO, Wanyin
Priority Data
202310388560.8
12.04.2023
CN
202410395122.9
02.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1629 | |
| EPO | Filing, Examination, Granting | 11611 | |
| Japan | Filing, Examination, Granting | 2014 | |
| South Korea | Filing, Examination, Granting | 1821 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,815
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided is a Levilactobacillus brevis ibiome003, and further provided are a pharmaceutical composition, a microbial agent composition and a food composition containing the strain. It is found that the microbial agent can effectively prevent, treat and relieve depression caused by various reasons.[French]
L'invention concerne une Levilactobacillus brevis ibie003 et concerne en outre une composition pharmaceutique, une composition d'agent microbien et une composition alimentaire contenant la souche. Il a été découvert que l'agent microbien peut efficacement prévenir, traiter et soulager la dépression survenant pour diverses raisons.[Chinese]
提供了一株短发酵剂乳杆菌（ Levilactobacillus brevis）ibiome003，并且提供了包含上述菌株的药物组合物和菌剂组合物以及食品组合物，并发现了上述菌剂能够有效预防、治疗、缓解多种原因引起的抑郁症。